Results 51 to 60 of about 6,607 (210)
Immunotoxin: A new tool for cancer therapy
, 2017 Cancer is one of the main reasons of death in the most countries and in Iran. Immunotherapy quickly became one of the best methods of cancer treatment, along with chemotherapy and radiation.
Mehdi Ghamgosha +4 more
core +1 more source
De Novo Synthesis in Cancer Immunotherapy: Applications and Prospects
MedComm, Volume 7, Issue 7, July 2026.De novo protein design creates novel structures for cancer immunotherapy, integrating rational design principles like modularity and specificity. Leveraging computational tools, it optimizes cytokine engineering, adoptive cellular therapy, and checkpoint regulation to enhance antitumor immunity.
Yang Jin, Yanfeng Wu, Jianhua Luo
wiley +1 more source
Antibodies, 2013 Human cytolytic fusion proteins (hCFPs) are comprised of a specific cell-surface-binding moiety and an effector molecule of human origin. In contrast to common immunotoxins, including bacterial or plant toxins, they are considered not to be immunogenic ...
Theo Thepen +7 more
doaj +1 more source
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma
Pharmaceutics, 2022 High-grade gliomas (HGG) are devastating diseases in children and adults. In the pediatric population, diffuse midline gliomas (DMG) harboring H3K27 alterations are the most aggressive primary malignant brain tumors. With no effective therapies available,
Julian S. Rechberger +6 more
doaj +1 more source
Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?
Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca +6 more
wiley +1 more source
Advanced Science, Volume 13, Issue 35, 24 June 2026.A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source
Cloning and Expression of Recombinant Immunotoxin using Diphtheria Toxin and Granulocyte Colony Stimulating Factor (G-CSF) [PDF]
Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk, 2016 Background: Immunotoxin (IT) is a directed toxin containing two distinct sections (immune and toxin parts) covalently bond using specific chemical or peptide linkers.
Fatemeh Donyapoor +2 more
doaj
Frontiers in Oncology, 2016 Glycolipids are complex molecules consisting of a ceramide lipid moiety linked to a glycan chain of variable length and structure. Among these are found the gangliosides, which are sialylated glycolipids ubiquitously distributed on the outer layer of ...
Jose Luis Daniotti +2 more
doaj +1 more source
ChemNanoMat, Volume 12, Issue 6, June 2026.Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo +3 more
wiley +1 more source
The future of antiviral immunotoxins [PDF]
Journal of Leukocyte Biology, 2016 Abstract There is a constant need for new therapeutic interventions in a wide range of infectious diseases. Over the past few years, the immunotoxins have entered the stage as promising antiviral treatments. Immunotoxins have been extensively explored in cancer treatment and have achieved FDA approval in several cases. Indeed, the design
Spiess, Katja +3 more
openaire +3 more sources